Tirzepatide is a newer glucose-lowering medication with agonist activity on the glucagon-like peptide (GLP)−1 receptor as well as on the glucose-dependent insulinotropic polypeptide (GIP) receptor. Tirzepatide exerts superior glycated hemoglobin (HbA1c) and overall plasma glucose lowering effects compared to GLP-1 agonists or basal insulin therapy. Furthermore, exploratory analyses have demonstrated that compared to insulin glargine, tirzepatide has a greater anti-albuminuric effects, and attenuates the decline in estimated glomerular filtration rate (eGFR).
